(PDF) Afatinib in Advanced NSCLC: A Profile of Its Use

Afatinib in Advanced NSCLC: A Profile of Its Use

Drugs and Therapy Perspectives - United Kingdom

doi 10.1007/s40267-018-0482-6

Full Text

Abstract

Available in full text

Categories

Date

February 1, 2018

Authors

Gillian M. Keating

Publisher

Springer Science and Business Media LLC

Related search

Osimertinib as First-Line Therapy in Advanced NSCLC: A Profile of Its Use

Drugs and Therapy Perspectives

English

P018 Afatinib Named Patient Use Program in Advanced NSCLC With Progression on Prior Therapy: Experience From Asian Centers

Journal of Thoracic Oncology

Respiratory Medicine

English

Afatinib in Locally Advanced/Metastatic NSCLC Harboring Common EGFR Mutations, After Chemotherapy: A Phase IV Study

Lung Cancer Management

English

P1.01-11 Named Patient Use Program for Afatinib in Advanced NSCLC With Progression on Prior Therapy: Experience From Asian Centers

Journal of Thoracic Oncology

Respiratory Medicine

English

Metreleptin in Lipodystrophy: A Profile of Its Use

Drugs and Therapy Perspectives

English

OA03 Afatinib Followed by Osimertinib in Real-World Patients With EGFR Mutation-Positive Advanced NSCLC: The Giotag Study

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-54 a Historical Comparison of Patients With Advanced NSCLC Harboring Uncommon EGFR Mutations Before and After the Approval of Afatinib in Japan

Journal of Thoracic Oncology

Respiratory Medicine

English

157P Second-Line Afatinib for Patients With Locally Advanced or Metastatic NSCLC Harbouring Common EGFR Mutations: A Phase IV Study

Journal of Thoracic Oncology

Respiratory Medicine

English